EDX Medical Group plc (LON:EDX), which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, has announced that it was informed on 9 November 2026 that Professor Sir Christopher Evans OBE, founder, board director and Chief Scientific Officer of the Company, purchased a total of 197,500 ordinary shares in the Company via open market trading on 6 November and 9 November 2026 at an average price of 7.5 pence per share.
Professor Evans now owns 136,417,793 shares in the Company, representing 31.62% of the issued share capital.
This announcement is made in accordance with Article 19(1) of the EU Market Abuse Regulation as incorporated into UK law through the European Union (Withdrawal) Act 2018.
The directors of the Company accept responsibility for the contents of this announcement.
| 1 | Details of PDMR / person closely associated with them (“PCA”) | |
| (a) | Name | Professor Sir Christopher Evans |
| 2 | Reason for the notification | |
| (a) | Position/status | PDMR / Chief Scientific Officer |
| (b) | Initial notification/amendment | Initial notification |
| 3 | Details of the Issuer | |
| (a) | Name | EDX Medical Group plc |
| (b) | Legal Entity Identifier code | 213800BZVJZTMCZ6DJ63 |
| 4 | Details of the transaction(s) | |
| (a) | Description of the financial instrument | Ordinary shares of £0.01 each |
| (b) | Identification Code | ISIN: GB00BNDMJS47 |
| (c) | Nature of the transaction | Purchase of shares on market |
| (d) | Currency | GBP |
| (e) | Price(s) and volume(s) | Price(s)Volume(s)£0.07467,500£0.07565,000£0.07565,000 |
| [(f) | Aggregated information- Aggregated volume- Price | 197,500 shares£0.075 |
| (g) | Date of the transaction | 06-11-2026 |
| (h) | Place of the transaction | XLON:AIMX |
